Global Chondrodermatitis Nodularis Helicis Market, By Treatment (Antibiotics, Corticosteroids, Collagen, Liquid nitrogen, Nitro-glycerine, Laser treatment, Surgery), Causes (Ear trauma, use of headphones or telephones, frostbite, systemic sclerosis, others),Diagnosis (biopsy), By End-Users (Clinics, Hospitals, Diagnostic centres, Home healthcare, others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) – Industry Trends and Forecast to 2030.
Chondrodermatitis Nodularis Helicis Market Analysis and Size
This condition was first described by the dermatologist Winkler in 1915, who stated eight cases and later by Foerster, who again reported a further four cases. The exact occurrence of CNH remains unknown. This condition usually affects the helix of the pinna, though in some cases, the antihelix also may also be affected. For this reason, many researchers have suggested renaming the condition to chondrodermatitis nodularis auricularis.
Data Bridge Market Research analyses that the chondrodermatitis nodularis helicis market is expected to reach USD 658.4 million by 2030, which is USD 500 million in 2022, and is expected to undergo a CAGR of 3.50% during the forecast period 2023 to 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Chondrodermatitis Nodularis Helicis Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Treatment (Antibiotics, Corticosteroids, Collagen, Liquid nitrogen, Nitro-glycerine, Laser treatment, Surgery), Causes (Ear trauma, use of headphones or telephones, frostbite, systemic sclerosis, others), Diagnosis (biopsy), End-Users (Clinics, Hospitals, Diagnostic Centres, Home healthcare, others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Novartis AG (Switzerland), Sanofi (France), Pfizer Inc. (U.S.), Johnson & Johnson Private Limited (U.S.), Abbott (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Bausch Health Companies Inc. (Canada), UCB S.A. (Belgium), AstraZeneca (U.K.), GSK plc (U.K.), Takeda Pharmaceutical Company Limited (Japan)
|
|
Market Opportunities
|
|
Market Definition
Chondrodermatitis Nodularis Helicis (CNH) is a type of inflammatory condition that majorly affects the cartilage of ear and skin. It is also known as nodular chondrodermatitis, Winkler disease, and chondrodermatitis nodularis chronica helicis. A painful bump is witnessed on the cartilage of ear. It usually presents as a painful nodule which is surrounded by an area of erythema and often prevents the patient from sleeping on the affected side. Lesions are witnessed in both on the helix and on the antihelix.
Chondrodermatitis Nodularis Helicis Market Dynamics
Drivers
- Prevalence of Chondrodermatitis Nodularis Helicis
The exact prevalence rate of CNH remains unknown. However, when not associated with autoimmune processes, it commonly affects middle aged men or above. Approximately 70-90% of patients are witnessed to be in this age group. But it may affect women and younger adults as well. CNH can occur in all ethnicities; though, it is more prevalent among fair-skinned people with a history of chronic sun exposure. Therefore, these growing cases of diseases increase the need and growth of the market.
- Greater Adoption of Biopsy
Diagnosis of this syndrome initiates with a clinical examination. Histopathological examination of a skin biopsy may help in the final diagnosis. Researchers and physicians recommend this to rule out systemic illnesses such as thyroid disease, scleroderma, and other collagen vascular diseases, particularly in adults under 40 years of age. The exact time that it takes to obtain the results will depend on the type of biopsy. In general, it may be ready within 1–2 days. Thus, it is definitely helping in the faster diagnosis and subsequent treatment processes.
Opportunities
- Increasing Demand of Treatment Processes
There are several treatment methods that are boosting the growth of the market. Pressure-relieving prosthesis or padding is a cost-effective and inexpensive method. The main aim of this method is to relieve pressure on the lesion. They are available in numerous forms, such as foam bandages attached to the head, self-adherent foam sponges, and doughnut pillows for sleeping. These methods showed huge success, mainly dependent upon patient compliance rates. Photodynamic therapy may be highly effective; though, a drawback of this modality is the requirement for numerous treatment sessions. Then, cryosurgery is another option to remove the lesion. Furthermore, electrocauterization or curettage is yet another treatment modality. Surgical treatment includes wide local excision followed by auricular reconstruction using skin grafts or local flaps, then removal of the lesion skin and cartilage, and also skin-sparing, cartilage-only excision techniques. Few clinicians have used topical and intralesional steroids; though, in the absence of interventions to increase physical pressure, steroids do not appear to be effective. This factor is boosting the market growth.
Restraints/Challenges
- Lack of Appropriate Treatments
There are several regions where the appropriate treatments are unavailable; thus, the patients with these rare syndromes are left behind. This factor in a way hampers the market growth. More awareness and sources are required to enable the treatments globally.
This chondrodermatitis nodularis helicis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the chondrodermatitis nodularis helicis market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Chondrodermatitis Nodularis Helicis Market Scope
The chondrodermatitis nodularis helicis market is segmented on the basis of treatment, causes, diagnosis, end-user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment
- Antibiotics
- Corticosteroids
- Collagen
- Liquid nitrogen
- Nitro-glycerine
- Laser treatment
- Surgery
Causes
- Ear trauma
- Use of headphones or telephones
- Frostbite
- Systemic sclerosis
- Others
Diagnosis
- Biopsy
End-User
- Clinics
- Hospitals
- Diagnostic Centres
- Home Healthcare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacies
- Others
Chondrodermatitis Nodularis Helicis Market Regional Analysis/Insights
The chondrodermatitis nodularis helicis market is analyzed and market size insights and trends are provided by treatment, causes, diagnosis, end-user and distribution channel as referenced above.
The major countries covered in the chondrodermatitis nodularis helicis market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is dominating the market in the forecast period because of the huge existence of large number of market players and growing clinical trials, well-developed healthcare sector and growing government support for R&D in this region.
Asia-Pacific is considered the most lucrative period because of the increased incidence of diseases and rising healthcare expenditure.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Chondrodermatitis Nodularis Helicis Market Share Analysis
The chondrodermatitis nodularis helicis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to chondrodermatitis nodularis helicis market.
Key players operating in the chondrodermatitis nodularis helicis market include:
- Novartis AG (Switzerland)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- Johnson & Johnson Private Limited (U.S.)
- Abbott (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Bausch Health Companies Inc. (Canada)
- AstraZeneca (U.K.)
- GSK plc (U.K.)
- Takeda Pharmaceutical Company Limited (Japan)
- Cadila Pharmaceuticals (India)
SKU-